Having more than one option available would allow clinicians to treat a wide spectrum of resistance mechanisms.
In this video from ASM 2016, Amanda Paschke, MD, of Merck, and Infectious Disease Advisor’s Michael Tapper, MD, discuss the importance of developing new medications, particularly for sepsis.
Dr Paschke explains that there is an urgent need for new drugs, and that it is important to have more than one option available to treat a wide spectrum of resistance mechanisms.
Enjoying our content?
Thanks for visiting Infectious Disease Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Infectious Disease Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.